The thiopurine methyltransferase TPMT *1/*3A genotype is associated with a better treatment outcome in the UK ALL97 trial for childhood acute lymphoblastic leukaemia; TPMT heterozygosity is not associated with secondary cancers
Auteurs principaux: | Lennard, L, Cartwright, C, Wade, R, Richards, S, Mitchell, C, Kinsey, S, Eden, T, Lilleyman, J, Vora, A |
---|---|
Format: | Conference item |
Publié: |
2010
|
Documents similaires
-
Detection of Thiopurine S-Methyltransferase (TPMT) Polymorphisms TPMT*3A, TPMT*3B and TPMT*3C in Children with Acute Lymphoblastic Leukemia
par: Nawar S. Mohammed, et autres
Publié: (2018-12-01) -
Thiopurine methyltransferase genotype-phenotype discordance and thiopurine active metabolite formation in childhood acute lymphoblastic leukaemia.
par: Lennard, L, et autres
Publié: (2013) -
Common Polymorphism’s Analysis of Thiopurine S-Methyltransferase (TPMT) in Iranian Population
par: Mehdi Azad, et autres
Publié: (2009-01-01) -
In Vitro Protein Stability of Two Naturally Occurring Thiopurine S‑Methyltransferase Variants: Biophysical Characterization of TPMT*6 and TPMT*8
par: Patricia Wennerstrand, et autres
Publié: (2017-08-01) -
Thiopurine methyltransferase (TPMT), nudix hydrolase 15 (NUDT-15) and methylene tetrahydrofolate reductase (MTHFR)polymorphisms in children with acute lymphoblastic leukaemia
par: Srikanth Marda, et autres
Publié: (2022-01-01)